Anti-VEGF Therapeutics Market Analysis
Explore In-Depth Anti-VEGF Therapeutics Market Analysis, Covering Detailed Segmentation and Geographical Insights for the Period of 2019 to 2030
Anti-VEGF Therapeutics Industry Insights
Product Insights
Eylea holds the largest market share, of 60%, in 2024, and it is also expected to maintain its position during the forecast period. This is attributed to the ongoing research and development activities in this area. For instance, Regeneron has been conducting a phase-2 proof-of-concept study comparing the 8 mg dose against the established 2 mg dose to investigate if a higher dose can benefit wet AMD patients.
Beovu is expected to gain momentum at the highest CAGR, of approximately 4%, in the coming years. Moreover, it received approval from EC for the management of visual impairment, owing to diabetic macular edema (DME), in March 2022, and thus, it can be used in all 27 EU member states as well as Iceland, Norway, and Liechtenstein. Therefore, the approvals from several organizations drive the market growth in this category.
The following products have been analyzed:
- Eylea (Largest Category)
- Lucentis
- Beovu (Fastest-Growing Category)
- Others
Disease Insights
AMD dominates the market with 55% share in 2024, owing to the increasing cases of AMD. For instance, around 2 million persons aged 50 years and more were blind as a result of AMD, and 6.22 million people had moderate-to-severe vision impairment (MSVI), as of 2020, globally. However, the age-standardized prevalence of AMD blindness decreased by more than 20% during 2000–2020, due to the increasing awareness and rising adoption of anti-VEGF medications.
The diabetic retinopathy category is projected to witness the highest CAGR, of 4.1%, during 2025–2030, owing to the surging incidences of DR, globally. For instance, from around 100 million in 2020, the number of adults with this condition is expected to rise to more than 150 million by 2045.
The report offers insights into the below-mentioned diseases:
- Macular Edema
- Diabetic Retinopathy (Fastest-Growing Category)
- Retinal Vein Occlusion
- Age-Related Macular Degeneration (Largest Category)
- Others
Distribution Channel Insights
Hospital pharmacies will generate the highest revenue in this market, of USD 15 billion, by the end of 2024. Most patients with eye diseases treatable with anti-VEGF therapeutics visit full-fledged hospitals for diagnosis and treatment by trained professionals. They are prescribed drugs right there, which many prefer to purchase from onsite drugstores, to avoid the hassles of going somewhere else and for the trust they place in these stores.
The online pharmacies category will witness the highest CAGR, of 5%, during the forecast period. This is attributed to the increasing preference for online shopping on account of the many conveniences it offers to customers. Moreover, to stop alleged drug-seeking behavior, many governments have mandated that drugs only be dispensed through online platform on presentation of a signed doctor’s prescription. Additionally, with the integration of blockchains by online drugstores, the possibility of prescription fraud would reduce further.
The following distribution channels are covered:
- Hospital Pharmacies (Largest Category)
- Retail Pharmacies
- Online Pharmacies (Fastest-Growing Category)
- Others
Regional Analysis
- The North American anti-vascular endothelial growth factor therapeutics market will hold the largest revenue share, of around 60%, in 2024.
- This is attributed to the improvements in healthcare infrastructure, technological advancements, proactive government actions, rise in consumer awareness, and increase in disease prevalence.
- The U.S. leads the North American market, as most of the major companies are headquartered in the country, providing early and easy access to the latest innovations to patients.
- Moreover, private companies along with educational institutes and other organizations are involved in new product development and research and development activities.
- The Canadian market for anti-VEGF therapeutics is likely to witness significant growth during the forecast period owing to the approvals received by companies for anti-VEGF medications.
- For instance, Health Canada has approved Samsung Bioepis and Biogen's BYOOVIZ, a Lucentis biosimilar for the treatment of neovascular (wet) AMD and visual impairment due to DME, among others.
- The APAC market size is likely to propel at the highest CAGR, of approximately 4%, during 2025–2030. Licensing agreements between companies are one of the major factors driving the market growth.
- For instance, PanOptica and Zhaoke Ophthalmology Limited have entered into a licensing agreement to develop and commercialize PAN-90806, a topical eye drop for the treatment of neovascular eye diseases, including wet AMD and DR, in China, South Korea, and Southeast Asia.
- Japan holds the largest revenue share in the APAC market currently.
- This is because the country ranks number one, in terms of the geriatric population, with more than 25% of the total population being above 65 years of age, resulting in high incidences of AMD and DR, among other diseases.
- Thus, companies are introducing new treatments for such diseases.
- For instance, Chugai Pharmaceutical has launched Vabysmo Intravitreal Injection 120 g/mL (faricimab) as an anti-VEGF/anti-Ang-2 bispecific antibody for the treatment of AMD associated with subfoveal choroidal neovascularization and DME, after receiving approval from the Ministry of Health, Labor and Welfare (MHLW) of Japan.
The following regions and countries have been studied:
- North America (Largest Regional Market)
- U.S. (Larger Country Market)
- Canada (Faster-Growing Country Market)
- Europe
- Germany (Largest Country Market)
- France
- U.K.
- Italy (Fastest-Growing Country Market)
- Spain
- Rest of Europe
- Asia-Pacific (APAC) (Fastest-Growing Regional Market)
- China
- India (Fastest-Growing Country Market)
- Japan (Largest Country Market)
- Australia
- Rest of APAC
- Latin America (LATAM)
- Brazil (Largest Country Market)
- Mexico (Fastest-Growing Country Market)
- Argentina
- Rest of LATAM
- Middle East and Africa (MEA)
- Saudi Arabia (Fastest-Growing Country Market)
- South Africa
- U.A.E. (Largest Country Market)
- Rest of MEA
Want a report tailored exactly to your business need?
Request CustomizationWe are Trusted by
Client Testimonials
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Unmatched Standards
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
Complete Data Security
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
*
*
*
Request the Free Sample Pages
*
*
*